Risk stratifi cation and therapeutics of neuroblastoma:the challenges remain

Pediatric oncology is a rapidly evolving and exciting field.Although advances have been made in this field through the integration of systematic basic laboratory and clinical research,treatment outcomes are still suboptimal for patients with a malignant solid tumor.Neuroblastoma,the most common extracranial solid tumor of childhood,accounts for 7%-8%of all cancers in children in the United States and United Kingdom.[1,2]It typically originates from the adrenal gland,sympathetic ganglia。